Кафедра нервових хвороб

Постійне посилання на фонд

https://repository.pdmu.edu.ua/handle/123456789/30

Переглянути

Перегляд Кафедра нервових хвороб за Автор "Ashraf, Ghulam Md."

Зараз показуємо 1 - 2 з 2
  • Ескіз недоступний
    Документ
    Cognitive and affective disturbances in patients with Parkinson's disease: Perspectives for classifying of motor/neuropsychiatric subtypes
    (Elsevier, 2022-06) Shkodina, Anastasiia D.; Tarianyk, Kateryna A.; Boiko, Dmytro I.; Zehravi, Mehrukh; Akter, Shamima; Ashraf, Ghulam Md.; Rahman, Md. Habibur; Шкодіна, Анастасія Дмитрівна; Таряник, Катерина Анатоліївна; Бойко, Дмитро Іванович
    Parkinson’s disease (PD) is a neurological disorder, related to rigidity, bradykinesia, and resting tremors, among other motor symptoms. It is noticed in the increasing frequency of neuropsychiatric disorders, which may be also caused by non-motor symptoms of PD. Treatment of PD is usually based on the classification of motor subtypes; however, it remains unclear whether motor subtypes have differences in the severity of psychiatric symptoms. It determines the importance of discovering possible neuropsychiatric subtypes of PD. We conducted a clinical study, which included group 1 - patients with postural instability and gait disorders dominant (PIGD) subtype, group 2 - patients with tremor dominant (TD) and indeterminate subtypes (non-PIGD), and group 3 - people who did not have CNS damage. We used the Montreal Cognitive Assessment, Russified 20-point version of the Toronto Alexithymia Scale, State-Trait Anxiety Inventory, and Beck Depression Inventory for assessment of the mental status. It was the first time that neuropsychiatric subtypes of PD had been investigated based on the condition of cognition and mood. Cluster analysis gave us the possibility to classify our patients by the following subtype: affective-cognitive PIGD, anxious PIGD, affective-cognitive non-PIGD, and non-PIGD without psychiatric symptoms. This indicates a closed link between psychiatric and motor symptoms, which can be used for the improved treatment of PD.
  • Ескіз недоступний
    Документ
    Drug reprofiling history and potential therapies against Parkinson’s disease
    (2022-10-26) Latif, Komal; Ullah, Aman; Shkodina, Anastasiia D.; Boiko, Dmytro I.; Rafique, Zakia; Alghamdi, Badrah S.; Alfaleh, Mohamed A.; Ashraf, Ghulam Md.; Шкодіна, Анастасія Дмитрівна; Бойко, Дмитро Іванович
    Given the high whittling down rates, high costs, and moderate pace of new medication, revelation, and improvement, repurposing “old” drugs to treat typical and uncommon illnesses is progressively becoming an appealing proposition. Drug repurposing is the way toward utilizing existing medications in treating diseases other than the purposes they were initially designed for. Faced with scientific and economic challenges, the prospect of discovering new medication indications is enticing to the pharmaceutical sector. Medication repurposing can be used at various stages of drug development, although it has shown to be most promising when the drug has previously been tested for safety. We describe strategies of drug repurposing for Parkinson’s disease, which is a neurodegenerative condition that primarily affects dopaminergic neurons in the substantia nigra. We also discuss the obstacles faced by the repurposing community and suggest new approaches to solve these challenges so that medicine repurposing can reach its full potential.